Lenalidomide: A review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion

Drugs

Volumn 73, Issue 11, 2013, Pages 1183-1196

  Syed, Yahiya Y ^a   Scott, Lesley J ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; PLACEBO; ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD TRANSFUSION; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 5Q; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAPAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGISTER; REVIEW; SWITZERLAND; THROMBOCYTOPENIA; TRANSFUSION DEPENDENT ANEMIA; TREATMENT DURATION; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; CHROMOSOME 5; COMPLICATION; ERYTHROCYTE TRANSFUSION; GENETICS; MACROCYTIC ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANEMIA; ANEMIA, MACROCYTIC; ANGIOGENESIS INHIBITORS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; ERYTHROCYTE TRANSFUSION; HUMANS; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84880840125     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0071-x     Document Type: Review

References (62)

1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83(1):71-86.
2. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-42.
3. Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res. 2011;35(12):1591-6.
4. Bacher U, Schnittger S, Kern W, et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol. 2009;88(12):1207-13.
5. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
6. Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115(22):5202-9.
7. Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168-78.
8. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
9. Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010;24(7):1283-9.
10. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.
11. Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. Curr Treat Options Oncol. 2011;12(4):354-68.
12. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
13. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
14. Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011;9(1):30-56.
15. Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26(6):1286-92.
16. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71(5):625-49.
17. Heise C, Carter T, Schafer P, et al. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010;10(10):1663-72.
18. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;. doi: 10.1186/1756-8722-2- 36.
19. Boyer DF, Attar E, Hasserjian RP. Fli-1 expression is increased in erythroblasts in MDS with DEL(5Q) and correlates with response to lenalidomide [abstract no. 1366]. Lab Invest. 2012;92(S1):325A-6A.
20. Jonasova A, Fuchs O, Vostry M, et al. The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment [abstract no. 274]. Leuk Res. 2011;35(Suppl. 1):S108.
21. Buesche G, Giagounidis A, Gohring G, et al. Mechanisms of action of lenalidomide on erythroblastic islands in patients with low- or intermediate-1-risk MDS with del(5q) chromosome abnormality [abstract no. 269]. Leuk Res. 2011;35(Suppl. 1):S106.
22. Ximeri M, Galanopoulos A, Klaus M, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95(3):406-14.
23. Belickova M, Cermak J, Dostalova Merkerova M, et al. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clin Lymphoma Myeloma Leuk. 2012;12(5):375-83.
24. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2):e35.
25. Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol. 2010;85(3):231-5.
26. Oliva EN, Cuzzola M, Aloe Spiriti MA, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol. 2013;92(1):25-32.
27. Venner CP, Woltosz JW, Nevill TJ, et al. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013;98(3):409-13.
28. Pellagatti A, Jadersten M, Forsblom A-M, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007;104(27):11406-11.
29. Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24(4):748-55.
30. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA. 2009;106(31):12974-9.
31. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971-9.
32. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025-37.
33. ® (lenalidomide) capsules product information. 2012. http://celgene.com.au/download/RevlimidPI.pdf. Accessed 30 April 2013.
34. Celgene Corporation. REVLIMID [lenalidomide] capsules, for oral use: prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/021880s031lbl.pdf. Accessed 30 April 2013.
35. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47(12):1466-75.
36. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-57.
37. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-65.
38. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-76.
39. Fenaux P, Giagounidis A, Selleslag D, et al. Effect of baseline EPO and prior erythropoiesis stimulating agents on RBC transfusion independence in Low-/Int-1-risk MDS with del5q treated with lenalidomide: a randomized phase 3 study (MDS-004) [abstract no. 0311]. Haematologica. 2010;95(Suppl. 2):125.
40. Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365-74.
41. Sekeres MA, Maciejewski JP, Giagounidis AAN, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26(36):5943-9.
42. Revicki DA, Brandenburg NA, Muus P, et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res. 2013;37(3):259-65.
43. Fenaux P, Giagounidis A, List AF, et al. Outcomes for patients (Pts) with low-/int-1-risk myelodysplastic syndromes (MDS) with del5q aged <65 years treated with lenalidomide (LEN) in MDS-003 and MDS-004: a retrospective combined analysis [abstract no. 1723]. Blood. 2011;118(21).
44. Giagounidis A, Hellstrom-Lindberg E, Fenaux P, et al. Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients [abstract no. 58]. Leuk Res. 2011;35(Suppl. 1):S21.
45. Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2012. doi: 10.1038/leu.2012.369.
46. Buckstein R, Alibhai S, Lam A, et al. Transfusion dependence and low hemoglobin have the greatest impact on quality of life in MDS patients - a tertiary care cross sectional and longitudinal study [abstract no. 2500]. Blood. 2009;114(22).
47. Oliva EN, Latagliata R, Lagana C, et al. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma. 2013. doi: 10.3109/10428194.2013.778406.
48. Sanchez-Garcia J, Del Canizo C, Such E, et al. A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion [abstract no. 64]. Leuk Res. 2011;35(Suppl. 1):S24.
49. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-4.
50. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
51. Hellstrom-Lindberg E, Giagounidis A, Selleslag D, et al. Update on safety and long-term outcomes in lenalidomide (LEN)-treated patients with red blood cell (RBC) transfusion-dependent low-/int-1-risk myelodysplastic syndromes (MDS) and del(5q) [abstract no. 0870 plus poster 1715]. Haematologica. 2012;97(s1):358-9.
52. Sekeres MA. Lenalidomide in MDS: 4th time's a charm. Blood. 2011;118(14):3757-8.
53. European Medicines Agency. Withdrawal assessment report for lenalidomide Celgene Europe. 2008. http://www.ema.europa.eu/docs/en-GB/document-library/ Application-withdrawal-assessment-report/2010/01/WC500065821.pdf. Accessed 17 April 2013.
54. Ades L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012;97(2):213-8.
55. Gohring G, Lange K, Hofmann W, et al. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia. 2012;26(2):356-8.
56. Fenaux P, Giagounidis A, Selleslag DL, et al. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality [abstract no. 6598]. J Clin Oncol. 2010;28(15).
57. Giagounidis A, Raza A, List AF, et al. Analysis of second primary malignancies in lenalidomide-treated patients with IPSS low- or Int-1-risk myelodysplastic syndromes [abstract no. 1704]. Blood. 2011;118(21).
58. Yang X, Brandenburg NA, Freeman J, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29(3):161-71.
59. Celgene Corporation. REVLIMID(R) granted Swissmedic approval for treatment of rare blood cancer [media release]. 21 Nov 2011. http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle- print&ID=1632356&highlight=.
60. Pharmaceuticals and Medical Devices Agency. Products Approved in FY 2010: New Drugs. 2010. http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2010. pdf. Accessed 21 Dec 2012.
61. European Medicines Agency. Revlimid (lenalidomide): summary of product characteristics. 2013. http://ec.europa.eu/health/documents/community-register/ 2013/20130613126109/anx-126109-en.pdf. Accessed 25 Jun 2013.
62. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v158-61.